| Document |
Document Title |
|
WO/2013/038314 |
The invention relates a method for preparation of betulonic acid or betulinic acid from betulin wherein the method comprises a stage for oxidizing betulin to betulonic aldehyde and/or betulinic aldehyde with Pd(ll)-catalyst catalyzed oxi...
|
|
WO/2013/038312 |
The present invention relates to a method for preparation of betulinic acid from betulin. The method comprises oxidizing betulin to betulinic and/or betulonic aldehyde with a ruthenium based catalyst catalyzed oxidation process in the pr...
|
|
WO/2013/038316 |
The present invention relates to a method for preparation of betulinic acid from betulin. The method comprises oxidizing betulin to betulinic acid with a catalyst of formula (5), e.g. 2,2,6,6-tetramethylpiperidine 1 - oxyl (TEMPO), in th...
|
|
WO/2013/020245 |
Disclosed are a compound characterized by the following formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof, wherein R3, L, and ...
|
|
WO/2012/160250 |
The present invention provides an improved method for obtaining a bark extract by hydrolysis and acidification in the presence of water. The method comprises the steps of subjecting birch bark to hydrolysis; separating the undissolved ba...
|
|
WO/2012/160250 |
The present invention provides an improved method for obtaining a bark extract by hydrolysis and acidification in the presence of water. The method comprises the steps of subjecting birch bark to hydrolysis; separating the undissolved ba...
|
|
WO/2012/109752 |
The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular o...
|
|
WO/2012/107513 |
The invention relates to processes for obtaining 6β,7β; 15β, 16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, commonly known as Drospirenone, as well as to intermediate compounds of formula (II) useful in said process.
|
|
WO/2012/023599 |
A process for producing a triterpene alcohol by carrying out the following steps (A)-(C) in this order: (A) hydrolyzing γ-oryzanol with an alkali; (B) mixing the resulting alkali hydrolysate with a low-polar organic solvent to extract t...
|
|
WO/2012/016860 |
The invention relates to a process for the preparation of Drospirenone in high yields and purity starting from a compound of formula (2) wherein R is a hydroxyl protective group as defined in the claims, through a sequence of oxidation, ...
|
|
WO/2011/113196 |
Preparation method of drospirenone is disclosed, which uses 3β,5-dihydroxy-6β,7β,15β,16β-dimethylene-5β-androster-
17, 20-epoxy as the starting material and comprises the following steps: oxidizing the hydroxyl group at position 3,...
|
|
WO/2011/060634 |
23-hydroxy-betulinic acid derivatives, including 3-oxo-23-hydroxy-betulinic acid, 3-oxo-23-hydroxy-dihydrobetulinic acid and 23-hydroxy-dihydrobetulinic acid, their preparation methods and medical uses as antitumor and anti-HIV agents ar...
|
|
WO/2010/146042 |
The invention relates to processes for obtaining steroids with a spirolactone group in position 17, particularly to industrially obtaining 6β,7β; 15β,16β-dimethylene-3-oxo-17α- pregn-4-ene-21,17-carbolactone, commonly known as Drosp...
|
|
WO/2010/142705 |
The present invention relates to substituted steroid compounds having the formula (I) Wherein R1 is H or halogen; R2 is H, (1C-4C)alkyl, (1C-4C)acyl, glucuronyl or sulfamoyl; R3 is H or halogen; R4 is H, (1C-4C)alkyl, (2C-4C)alkenyl or (...
|
|
WO/2010/134830 |
Formule (I) and (II). The present invention relates to the use of a new lupane derivative of general formula (I) or (II), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, for preventin...
|
|
WO/2010/133687 |
The present invention relates to a compound with the following formula (I), or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for tr...
|
|
WO/2010/118023 |
Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.
|
|
WO/2010/114305 |
The present invention relates to a PEGylated betulin derivative, and a cosmetic composition containing the same. The PEGylated betulin derivative of the present invention is water-soluble and has an excellent UV blocking effect, a white ...
|
|
WO/2010/114305 |
The present invention relates to a PEGylated betulin derivative, and a cosmetic composition containing the same. The PEGylated betulin derivative of the present invention is water-soluble and has an excellent UV blocking effect, a white ...
|
|
WO/2010/058795 |
Provided is an antioxidant which is highly safe, inhibits oxidation of biological components, in particular, lipids and is usable as a drug, a food or a drink, a food additive, an external skin preparation and so on. A compound selected...
|
|
WO/2010/028487 |
The instant application is directed to bidesmosidic betulin and betulinic acid saponin derivatives of formula (I), and use thereof as antitumor agents. In particular, said compounds are effective in treating lung carcinomas, colorectal a...
|
|
WO/2009/146811 |
The present invention relates to C-ring-substituted pregn-4-ene-21,17-carbolactones of the general formula I in which R6,7 is an α- or β-methylene and R9 is a hydrogen atom and R11 is a bromine, chlorine or fluorine atom or R9 and R11 ...
|
|
WO/2009/111574 |
Described herein are bismethylene-17α carbolactone derivatives having progestational and/or antimineralocorticoid and/or aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.
|
|
WO/2009/100532 |
The invention relates to 17ß lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the inventi...
|
|
WO/2009/083270 |
The invention relates to (15, 16)-methylene-steroid-(17, 17)-lactol-derivates with general chemical formula (I) and the tautomer forms thereof with general chemical formula (Ia) wherein R4, R6a, R6b, R7, R18, R22 and Z have the designati...
|
|
WO/2009/083268 |
The invention relates to 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (1) wherein the radicals Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the designations given in claim 1, and to the solv...
|
|
WO/2009/083272 |
The invention relates to 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-2
1-carboxylic acid γ-lactone derivatives having a gestagen effect. They are of general chemical formula (I) wherein Z is selected from the group compri...
|
|
WO/2009/083271 |
The invention relates to 15,16-methylene-17-(1 '-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (I), wherein Z, R4, R6a, R6b, R7 and R18 have the designations given in claim 1, and to the solvates, hydrat...
|
|
WO/2009/082818 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082818 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/083266 |
The invention relates to 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivatives with the chemical formula (I) wherein R4, R6a, R6b, R7, R15, R16a, R16b, R18 and Z have the designations given in claim 1, and to the solvates, ...
|
|
WO/2009/082819 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/083272 |
The invention relates to 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-2
1-carboxylic acid γ-lactone derivatives having a gestagen effect. They are of general chemical formula (I) wherein Z is selected from the group compri...
|
|
WO/2009/083267 |
The invention relates to steroid-17, 17-lactol-derivatives with the chemical formula (I) and the tautomer forms thereof with general chemical formula (Ia) wherein R4, R6a, R6b, R7, R15, R16a, R16b, R18, R22and Z have the designations giv...
|
|
WO/2009/083268 |
The invention relates to 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (1) wherein the radicals Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the designations given in claim 1, and to the solv...
|
|
WO/2009/083267 |
The invention relates to steroid-17, 17-lactol-derivatives with the chemical formula (I) and the tautomer forms thereof with general chemical formula (Ia) wherein R4, R6a, R6b, R7, R15, R16a, R16b, R18, R22and Z have the designations giv...
|
|
WO/2009/082819 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/083269 |
The invention relates to a 15, 16-methylene-17-hydroxy-19-nor-21 -carboxylic acid-steroid γ-lactone-derivative with general chemical formula (I) wherein R4, R6a, R6b, R7 and Z have the designations given in claim 1, and to the solvates,...
|
|
WO/2009/059765 |
The present invention describes a process for the preparation of drospirenone (I) using androstendione as a starting material. In particular, androstendione protected on carbonyl group in position 3 as an enol-ether is functionalized in ...
|
|
WO/2009/059765 |
The present invention describes a process for the preparation of drospirenone (I) using androstendione as a starting material. In particular, androstendione protected on carbonyl group in position 3 as an enol-ether is functionalized in ...
|
|
WO/2009/020231 |
Disclosed are: a protein having an activity of oxidizing a dammarane triterpene; a gene encoding the protein; and use of the protein or the gene. Specifically disclosed are: a protein having an activity of oxidizing a dammarane triterpen...
|
|
WO/2009/012955 |
A process for the preparation of Drospirenone (I) according to the scheme (A) wherein the substituent R is defined in the description. The process improves the product yield and purity by reducing the formation of undesired side-products...
|
|
WO/2009/012955 |
A process for the preparation of Drospirenone (I) according to the scheme (A) wherein the substituent R is defined in the description. The process improves the product yield and purity by reducing the formation of undesired side-products...
|
|
WO/2009/000923 |
The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)- 17β-hydroxysteroids of the formula (I) starting from 17-ketosteroids of the formula (III) via the intermediates of the formula (V) wherein the rad...
|
|
WO/2009/000923 |
The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)- 17β-hydroxysteroids of the formula (I) starting from 17-ketosteroids of the formula (III) via the intermediates of the formula (V) wherein the rad...
|
|
WO/2008/152112 |
The 17ß-cyano-19-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, wherein R...
|
|
WO/2008/151746 |
The 17ß-cyano-19-nor-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, where...
|
|
WO/2008/151746 |
The 17ß-cyano-19-nor-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, where...
|
|
WO/2008/152112 |
The 17ß-cyano-19-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, wherein R...
|
|
WO/2008/151745 |
The 17ß-cyano-18a-homo-19-nor-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO...
|
